Pharmacokinetic Study of Rezafungin in Patients With Suspected Intra-Abdominal Candidiasis

Inclusion Criteria: * Patients with suspicion, confirmed or not, of candidiasis peritonitis or intra-abdominal infection by Candida spp. who, after having received information about the design, the purpose of the study, the possible risks that may arise from it and that they can refuse to collaborate at any time, give written consent to participate in the study. * Be over 18 years of age * Understand the purpose of the study and be available to perform the visits and procedures established in the protocol * In women: negative urine pregnancy test performed in the 7 days prior to the start of study treatment in women of childbearing age and if \< 2 years have passed after menopause * Patients with signs of peritonitis or intra-abdominal infection showing refractoriness after at least 48 hours of empirical or specific antibiotherapy and in whom candidiasis infection is suspected. * Patients with abdominal or peritoneal drainage with permeable debit that allows obtaining peritoneal samples through it. Exclusion Criteria: * Patients in whom there is any contraindication for use according to the established in the technical data sheet or known hypersensitivity to rezafungin or who, according to the investigator's criteria, it is not advisable to participate. * Patients who do not present suspicion of intra-abdominal candidiasis infection or who are receiving antifungal treatment for another reason. * Patients receiving another antifungal drug during rezafungin administration.